What Anumana Announced About Its Pulmonary Hypertension ECG Clearance
Anumana said on 28 March 2026 that it received FDA 510(k) clearance for an ECG-AI algorithm that looks for pulmonary hypertension on a standard 12-lead ECG, and the company describes it as the first such algorithm cleared for that test. Anumana reports 73 percent sensitivity and 74.4 percent specificity in adults who came in short of breath, from a multi-centre study of 21,066 patients at five United States health systems. The company says the algorithm was developed using more than 250,000 de-identified patient records from Mayo Clinic.
Why the Anumana Pulmonary Hypertension Clearance Matters to Cardiology Buyers
Pulmonary hypertension is usually confirmed with tests that cost more and take longer than an ECG, so a cleared screening signal on a cheap test is worth a look for a cardiology service line. The reported specificity of 74.4 percent also means a large number of people without the condition would be flagged, and somebody has to work through those results. A buyer should price the follow-up workload, not only the software.
Where the Anumana Update Comes From
Anumana is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the Anumana Pulmonary Hypertension Clearance
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start with the 510(k) indications for use and check whether the cleared claim is limited to patients who present short of breath.
- Then we would ask Anumana for the published multi-centre study and the false positive rate at the threshold the product ships with.
- We would model who reviews a flag and what the next test costs, because a screening signal only pays off if the follow-up exists.